Wedbush Has Lowered Expectations for Werewolf Therapeutics (NASDAQ:HOWL) Stock Price

Werewolf Therapeutics (NASDAQ:HOWL) had its target price decreased by equities research analysts at Wedbush from $8.00 to $6.00 in a research report issued on Friday,Benzinga reports. The firm currently has an “outperform” rating on the stock.

Other equities analysts have also issued reports about the company. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Werewolf Therapeutics in a research note on Wednesday, March 12th. JMP Securities cut their price objective on shares of Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating on the stock in a research report on Tuesday, January 14th.

Werewolf Therapeutics Trading Down 8.1 %

HOWL opened at $0.80 on Friday. Werewolf Therapeutics has a 1-year low of $0.60 and a 1-year high of $5.73. The company has a current ratio of 10.10, a quick ratio of 10.10 and a debt-to-equity ratio of 0.29. The company has a market cap of $35.89 million, a P/E ratio of -0.52 and a beta of 0.48. The company’s 50 day moving average is $0.95 and its 200-day moving average is $1.43.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.04. Werewolf Therapeutics had a negative return on equity of 58.83% and a negative net margin of 578.80%. Equities research analysts predict that Werewolf Therapeutics will post -1.56 earnings per share for the current fiscal year.

Institutional Trading of Werewolf Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC grew its position in Werewolf Therapeutics by 2.4% in the 4th quarter. Geode Capital Management LLC now owns 702,558 shares of the company’s stock worth $1,040,000 after purchasing an additional 16,569 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of Werewolf Therapeutics by 7.3% in the fourth quarter. Northern Trust Corp now owns 244,390 shares of the company’s stock worth $362,000 after acquiring an additional 16,640 shares during the period. Bridgeway Capital Management LLC grew its holdings in Werewolf Therapeutics by 24.4% during the 4th quarter. Bridgeway Capital Management LLC now owns 109,586 shares of the company’s stock valued at $162,000 after buying an additional 21,500 shares in the last quarter. Deutsche Bank AG grew its stake in Werewolf Therapeutics by 450.7% during the fourth quarter. Deutsche Bank AG now owns 101,626 shares of the company’s stock valued at $150,000 after acquiring an additional 83,172 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Werewolf Therapeutics by 33.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock valued at $93,000 after purchasing an additional 23,852 shares in the last quarter. 64.84% of the stock is owned by hedge funds and other institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.